<DOC>
	<DOCNO>NCT01570751</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial confirm efficacy IDeg ( insulin degludec ) versus IGlar ( insulin glargine ) control glycaemia . Subjects continue pre-trial metformin treatment .</brief_summary>
	<brief_title>A Trial Comparing Efficacy , Patient-reported Outcomes Safety Insulin Degludec 200 U/mL v Insulin Glargine Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes Current treatment daily insulin glargine vial daily dose equal 65 U equal 100 U Current treatment stable dose metformin plus/minus one additional oral antidiabetic drug ( OAD ) least 12 week Glycosylated haemoglobin ( HbA1c ) equal 7.5 % Current treatment insulin insulin glargine vial Treatment thiazolidinediones glucagonlike peptide1 ( GLP1 ) receptor agonist within 12 week Stroke ; heart failure ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Suffer cancer ( except basal cell skin cancer squamouscell cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>